Celltech rises on encouraging test results
Wednesday 10 May 1995
Clinical trials for three promising new medical compounds are continuing to go well for Celltech, the biotechnology company, which floated at 250p nearly 18 months ago.
The encouraging progress, combined with news that interim losses have been cut by £300,000 to £4.1m, was well received by the stock market, which marked up Celltech's shares by 2.5p to 307p yesterday.
Peter Fellner, chief executive, said: "The trials are very much on track and there have been no unpleasant surprises as some others in the sector have had." The second phase of studies to determine whether the compounds actually work is now under way, he said.
None of the expected side-effects have shown up in a new oral treatment for mild and moderate asthma, code-named CDP 840, which could be submitted for licensing in 1998. The potential for the drug, being developed with Merck, should be clearer by the end of this year, Mr Fellner said. The market is huge, with $6bn being spent on existing products like Ventolin and Tilade last year.
But, if tests go well, Celltech's first approvals are likely to be for a drug being developed with Bayer to combat inflammatory bowel disorders, called CDP 571, and an anti-leukaemia compound that American Home Products is backing, entitled CDP 771. Mr Fellner said filings could come as early as 1997.
Celltech differentiates itself from other recent biotechnology offerings by its higher levels of external income. Turnover from its business making antibodies for groups like Roche and Johnson & Johnson rose from £6.5m to £7.2m in the six months to March. With interest income - £900,000 in the half-year, down from £1m before - that is meant to fund half the research and development budget, with the rest coming from big drug company partners. Mr Fellner was pleased with the fall in half-year losses, despite having raised R&D spending by £1m to £8.8m last year.
- 1 Scottish referendum: So how about the English now being given a chance to split from England?
- 2 Stamford Hill council removes 'unacceptable' posters telling women which side of the road to walk down
- 3 Kim Kardashian 'nude pictures' leaked on 4chan weeks after Jennifer Lawrence 'The Fappening' scandal
- 4 Matthew Miller: American sentenced to hard labour in North Korea 'wanted to be Snowden II'
- 5 Iranian blogger found guilty of insulting Prophet Mohammad on Facebook sentenced to death
Stamford Hill council removes 'unacceptable' posters telling women which side of the road to walk down
Kim Kardashian 'nude pictures' leaked on 4chan weeks after Jennifer Lawrence 'The Fappening' scandal
Iranian blogger found guilty of insulting Prophet Mohammad on Facebook sentenced to death
4Chan naked photos leak: Celebrity Twitter reactions to the mass breach of privacy
Hitler’s former food taster reveals the horrors of the Wolf’s Lair
Scottish independence referendum: A nation divided against itself
Scottish referendum results: Cross-party consensus collapses amid Tory-Labour spat on the 'English question'
Scottish independence: David Cameron is becoming the 'George Bush of Britain'
Russia freezes Ukraine into submission: Kiev admits country doesn't have enough fuel for winter
Archbishop of Canterbury admits doubts about existence of God
Portuguese academic says British are 'filthy, violent and drunk'
iJobs Money & Business
£400 - £450 Per Day: Clearwater People Solutions Ltd: **URGENT CONTRACT ROLE**...
Up to £100k or £450p/d: Saxton Leigh: My client is a leading commodities tradi...
£320 - £330 per day: Ashdown Group: The Ashdown Group have been engaged by a l...
To £75,000 + Pension + Benefits + Bonus: Saxton Leigh: My client is looking f...